top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


Q3 MedTech Earnings: Procedure-Driven Growth Meets Capital-Spending Pressure
Q3 2026 medtech results showed a widening gap between fast-growing innovators and companies facing pressure in key product lines. Abbott led among larger players, while Profound Medical and IRadimed posted strong growth from smaller bases. MiMedx and Dentsply Sirona struggled with revenue declines, highlighting how product mix and demand can shape performance across the sector.
sharonshieldsconsu
Nov 123 min read


Integrating Teams After M&A or Strategic Partnerships
Value is driven by what happens bringing together individuals and teams In life sciences, mergers, carve‑outs and strategic alliances are now core to how pipelines advance and products reach patients. But while the deal thesis is usually about science, assets and markets, value is delivered (or destroyed) by what happens with people and ways of working in the first 12–18 months. This year has seen so many significant acquisition, across biotech and medtech, a few of the most
sharonshieldsconsu
Nov 126 min read


GLP-1s Beyond Obesity: What the Evidence Really Shows
GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology.
Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders:
In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and
sharonshieldsconsu
Sep 283 min read


Tilting the Scales: GLP‑1 Drugs, Obesity, and Who Gets to Rewrite Their Biology
GLP‑1 weight‑loss drugs started as diabetes medicines. Now they’re quietly becoming one of the most powerful tools in obesity treatment — and they’re still evolving.
The science is advancing quickly. The harder question is whether access, cost, and policy will keep up.
sharonshieldsconsu
Aug 23 min read
bottom of page